tndm-20201105
false000143813300014381332020-07-292020-07-29

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 8-K
____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2020
____________________________
Tandem Diabetes Care, Inc.
(Exact name of registrant as specified in its charter)
_________
Delaware001-3618920-4327508
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
11075 Roselle Street92121
San Diego California(Zip Code)
(Address of principal executive offices)
 Registrant’s telephone number, including area code: (858366-6900
N/A
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassSymbolName of Exchange on Which Registered
Common Stock, par value $0.001 per shareTNDMNASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
___________________________




Item 2.02    Results of Operations and Financial Condition.

On November 5, 2020, we issued a press release reporting our financial results for the quarter ended September 30, 2020. This press release has been furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

The information under this Item 2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits
    
(d)     Exhibits.

 Number
Description
99.1






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc.
By:
/s/ David B. Berger
David B. Berger
Executive Vice President, Chief Legal & Compliance Officer
Date: November 5, 2020

Document
Exhibit 99.1


https://cdn.kscope.io/ff22082f2510b38d4f3fb2b3cdc15802-tndmlogoa181.jpg

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900 x7005
IR@tandemdiabetes.com


FOR IMMEDIATE RELEASE

Tandem Diabetes Care Announces Third Quarter 2020 Financial Results
and Updated Full Year 2020 Sales Guidance

San Diego, November 5, 2020 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2020 and updated its sales guidance for the year ending December 31, 2020.

Third Quarter 2020 Highlights

In comparing the third quarter of 2020 to the same period of 2019:
Worldwide pump shipments increased 23 percent to 22,021 pumps from 17,839 pumps
Sales increased 31 percent to $123.6 million from $94.7 million
Operating margin improved to negative 1 percent from negative 6 percent

“Our t:slim X2 with Control-IQ technology drove record sales in the third quarter and we are excited to have commenced its launch outside the United States,” said John Sheridan, president and chief executive officer. “The third quarter was a remarkable demonstration of our employees’ commitment to progressing our business commercially, operationally and strategically, while focusing on customer care and preparing for future growth.”

Third Quarter 2020 Financial Results

Domestic pump shipments increased 33 percent to 18,380 pumps in the third quarter of 2020 from 13,814 pumps in the same period of 2019. Domestic sales were $107.5 million, or an increase of 36 percent compared to $78.8 million in the third quarter of 2019. International pump shipments decreased 10 percent to 3,641 pumps in the third quarter of 2020 from 4,025 pumps in the same period of 2019. International sales were $16.1 million, or an increase of 2 percent compared to $15.8 million in the third quarter of 2019.
Gross profit for the third quarter of 2020 increased 29 percent to $65.3 million, compared to $50.7 million for the same period of 2019. Gross margin was 53 percent in the third quarter of 2020 and 54 percent in the same period of 2019. These included a non-cash stock-based compensation charge of $2.1 million in the third quarter of 2020 compared to $1.8 million for the same period of 2019. Royalty expense was $1.7 million in the third quarter of 2020, compared to no royalty expense in the third quarter of 2019.

For the third quarter of 2020, operating expenses totaled $66.3 million, compared to $56.7 million for the same period of 2019. Operating expenses included a non-cash charge for stock-based compensation of $10.7 million, compared to stock-based compensation of $15.5 million for the same period of 2019. Operating loss totaled $1.0 million, compared to $6.0 million for the same period of 2019. Operating margin for the third quarter of 2020 was negative 1 percent compared to negative 6 percent for the same period of 2019. For the third quarter of 2020, adjusted EBITDA(1) was $14.8 million or 12 percent of sales, compared to $12.7 million, or 13 percent of sales, for the same period of 2019.

1

Exhibit 99.1
Net loss for the third quarter of 2020 was $9.4 million, which included a $3.6 million non-cash charge for the change in fair value of certain outstanding warrants and $4.9 million of interest expense related to the Company’s convertible debt offering, of which $3.8 million is non-cash. This is compared to a net loss of $2.9 million for the third quarter of 2019, which included a $2.3 million non-cash gain for the change in fair value of certain warrants outstanding at that time.

(1) EBITDA is a non-GAAP financial measure defined as net income (loss) excluding income taxes, interest and other non-operating items and depreciation and amortization. Adjusted EBITDA further adjusts for the change in fair value of common stock warrants and non-cash stock-based compensation expense. This definition of Adjusted EBITDA may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Adjusted EBITDA is a key measure used by the Company to evaluate operating performance, generate future operating plans and make strategic decisions for the allocation of capital. The Company presents Adjusted EBITDA to provide information that may assist investors in understanding its financial results. However, Adjusted EBITDA is not intended to be a substitute for net loss.

Cash Balance and Liquidity

As of September 30, 2020, the Company had $464.5 million in cash, cash equivalents and short-term investments. This represents a $38.2 million increase in the third quarter of 2020 and a $288.1 million increase since December 31, 2019. The increase in cash, cash equivalents and short-term investments includes net proceeds of $244.6 million from the Company’s convertible debt transaction during the second quarter.

2020 Guidance

For the year ending December 31, 2020, the Company is updating its sales guidance estimated to be in the range of $465 million to $475 million, which includes international sales of approximately $70 million to $75 million. This represents an annual sales growth of 28 percent to 31 percent compared to 2019. The Company’s prior sales guidance for 2020 was estimated to be in the range of $450 million to $465 million.

Non-GAAP Financial Measures

Certain non-GAAP financial measures are presented in this press release, including adjusted EBITDA, to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. We believe these non-GAAP financial measures are important indicators of our operating performance because they exclude items that are unrelated to, and may not be indicative of, our core operating results. These non-GAAP financial measures, as we calculate them, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent, and should not be considered to be more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. To the extent we utilize such non-GAAP financial measures in the future, we expect to calculate them using a consistent method from period to period. A reconciliation of each of the GAAP financial measures to the most directly comparable non-GAAP financial measures has been provided under the heading “Reconciliation of GAAP versus Non-GAAP Financial Results” in the financial statement tables attached to this press release. Consistent with SEC regulations, we have not provided a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures in reliance on the “unreasonable efforts” exception set forth in the applicable regulations, because there is substantial uncertainty associated with predicting any future adjustments that we may make to our GAAP financial measures in calculating our non-GAAP financial measures.

Conference Call

The Company will hold a conference call and simultaneous webcast today at 4:30pm Eastern Time (1:30pm Pacific Time). The link to the webcast will be available by accessing the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at http://investor.tandemdiabetes.com, and will be archived for 30 days. To listen to the conference call via phone, please dial 855-427-4396 (U.S./Canada) or 484-756-4261 (International) and use the participant code “8072078.”

2

Exhibit 99.1

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2 insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

Tandem Diabetes Care is a registered trademark and t:slim X2 and Control-IQ are trademarks of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.


Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding, among other things, the Company’s projected financial results. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, the Company’s ability to achieve projected financial results will be impacted by market acceptance of the Company’s existing products and products under development by physicians and people with diabetes; the Company’s ability to establish and sustain operations to support international sales, including expansion into additional geographies; changes in reimbursement rates or insurance coverage for the Company’s products; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; the Company’s ability to complete the development and launch new products when anticipated; the potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company’s products obsolete or less desirable; the depth and duration of the evolving COVID-19 pandemic, and the global response thereto; reliance on third-party relationships, such as outsourcing and supplier arrangements; global economic conditions; and other risks identified in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents that the Company files with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.




# # #


3

Exhibit 99.1
TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
September 30,December 31,
20202019
(Unaudited)
Assets
Current assets:
Cash and cash equivalents and short-term investments$464,522 $176,458 
Accounts receivable, net52,104 46,585 
Inventories70,644 49,073 
Other current assets5,023 4,025 
Total current assets592,293 276,141 
Property and equipment, net49,320 32,923 
Operating lease right-of-use assets21,325 15,561 
Other long-term assets10,050 1,485 
Total assets$672,988 $326,110 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable, accrued expenses and employee-related liabilities$57,374 $54,079 
Deferred revenue5,210 3,869 
Common stock warrants17,404 23,509 
Operating lease liabilities9,365 6,320 
Other current liabilities16,153 11,619 
Total current liabilities105,506 99,396 
Convertible senior notes, net - long-term199,120 — 
Operating lease liabilities - long-term17,893 14,063
Other long-term liabilities23,925 17,672 
Total liabilities346,444 131,131 
Total stockholders’ equity326,544 194,979 
Total liabilities and stockholders’ equity$672,988 $326,110 
4

Exhibit 99.1
TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Sales$123,603 $94,657 $330,765 $253,907 
Cost of sales58,290 43,974 160,801 119,967 
Gross profit65,313 50,683 169,964 133,940 
Operating expenses:
Selling, general and administrative50,228 44,649 150,385 120,173 
Research and development16,094 12,038 46,198 32,632 
Total operating expenses66,322 56,687 196,583 152,805 
Operating loss(1,009)(6,004)(26,619)(18,865)
Total other income (expense), net(8,360)3,175 (26,701)(8,468)
Loss before income taxes(9,369)(2,829)(53,320)(27,333)
Income tax expense (benefit)39 72 (1,938)72 
Net loss$(9,408)$(2,901)$(51,382)$(27,405)
Net loss per share, basic$(0.15)$(0.05)$(0.85)$(0.47)
Net loss per share, diluted$(0.15)$(0.09)$(0.85)$(0.47)
Weighted average shares used to compute basic net loss per share61,529 58,801 60,568 58,268 
Weighted average shares used to compute diluted net loss per share61,529 59,196 60,568 58,268 

5

Exhibit 99.1
Reconciliation of GAAP versus Non-GAAP Financial Results
(in thousands)Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
GAAP net loss$(9,408)$(2,901)$(51,382)$(27,405)
Income tax expense (benefit)39 72 (1,938)72 
Interest income and other, net(143)(854)(1,235)(2,381)
Interest expense4,855 — 8,030 — 
Depreciation and amortization2,989 1,484 7,024 4,430 
EBITDA(1,668)(2,199)(39,501)(25,284)
Change in fair value of common stock warrants3,648 (2,321)19,906 10,849 
Stock-based compensation expense12,837 17,231 45,123 39,386 
Adjusted EBITDA$14,817 $12,711 $25,528 $24,951 

6